Figure 1.
Figure 1. Mutation profile of patient cohort at diagnosis. (A) Heat map detailing mutation distribution among patient cohort with individual cytogenetic risk stratification and relapse/nonrelapse status post–allo-SCT. (B) Frequency of mutations in the cohort. (C) The number of mutations detected per patient in our cohort. (D) Comparison of our cohort with 2 published cohorts of de novo AML patients from the Cancer Genome Atlas (TCGA)7 and Papaemmanuil et al11 (Papa). TCGA and Papa datasets were curated to exclude mutations that would not have been covered by our NGS panel (TCGA-restricted and Papa-restricted). Fisher’s exact test was used to compare frequency of mutations in the indicated genes between our cohort and the restricted TCGA and Papa cohorts. Genes and frequencies highlighted in blue are those where P < .05.

Mutation profile of patient cohort at diagnosis. (A) Heat map detailing mutation distribution among patient cohort with individual cytogenetic risk stratification and relapse/nonrelapse status post–allo-SCT. (B) Frequency of mutations in the cohort. (C) The number of mutations detected per patient in our cohort. (D) Comparison of our cohort with 2 published cohorts of de novo AML patients from the Cancer Genome Atlas (TCGA) and Papaemmanuil et al11  (Papa). TCGA and Papa datasets were curated to exclude mutations that would not have been covered by our NGS panel (TCGA-restricted and Papa-restricted). Fisher’s exact test was used to compare frequency of mutations in the indicated genes between our cohort and the restricted TCGA and Papa cohorts. Genes and frequencies highlighted in blue are those where P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal